The shift
SaaS has customer success. Healthcare never built it for champions.
SaaS figured it out. When closing the deal stopped being the hard part, they built an entire discipline for what came after. Clinical innovation is twenty years behind that realization.
Same shape, one step short. Healthcare has the start and the finish, and nothing to carry a champion between them.
Pilot Purgatory
You built the product. You found your champion. And then, somehow, nothing moved.
70% of healthcare technology pilots never convert. That is Pilot Purgatory. Every quarter in Pilot Purgatory is a quarter of runway spent proving nothing.
What the first champion's data showed
Asclepii, a JumpStart company, started where technologies stall.
In 2025 Asclepii had a cleared wound care product, a handful of clinicians who liked using it, and no way to make sense of what they were seeing: which findings mattered, what would count as evidence, or what the path to product-market fit looked like. In its co-founder's words, the company "loved the idea of real-world evidence" and "didn't know what it meant operationally."
A physician running an independent wound care practice in Colorado, serving patients most studies exclude, ran Poseidon under a Champion Success protocol: success defined before enrollment, outcomes pre-specified, every measurement chart-verified.
mean wound area reduction across all wound types; threshold set before enrollment at 50%
mean time to closure. Chronic venous leg ulcers closed in 4 and 6 weeks against a published 12 to 16 week benchmark
infections in 18 safety assessments, against published rates of 3.5% (post-surgical) to 47.7% (burn)
cost avoided per VLU patient from 3 to 12 fewer visits at $200 to $300 a visit; one prevented infection avoids $5,800 or more
Weeks to closure against the published benchmark for each wound type
What that meant for the clinic
Visits moved from weekly to biweekly for multiple patients; visit frequency recorded as reduced at 4 of 5 survey points.
Patients discharged. In the coordinator's words at the November survey: "4 out of 6 of my patients using the hydrogel have completely healed and are now discharged."
Willingness to continue was unanimous across all 6 provider surveys, with confidence moving from select patients to broad use within two months.
In a population most studies exclude: 83% of wounds in high anatomic-risk locations, 83% of patients with comorbidities, documented non-adherence.
What the first result made possible
A multi-site wound care network in the Midwest was already trying Poseidon on a few patients, with no structure and no decision in sight. The first champion's chart-verified result gave the network's leadership something to decide on and showed where the product did its best work, so the network could be pointed at the patients where it would matter most. In May 2026, eleven months after the first champion enrolled her first patient, the network's leadership approved Poseidon across its sites, a decision that puts the product in front of hundreds of patients every month. This is the compounding effect of real-world evidence collected and reported in precisely the form the next champion needs to make a fast, evidence-based decision: each site's result gives the next provider the indication, patient selection criteria and treatment protocol under which the product performs, and gives its leadership a reason to commit at scale. That is product-market fit in healthcare: institutional adoption that repeats, site after site.
Asclepii with Champion Success
first enrollment to network approval
Conventional path
first clinical use to multi-site adoption
1 VBIA real-world evidence report, Feb 2026: prospective observational quality-improvement study, 5 active patients, 18 observations, Oct 2025 to Jan 2026; visit cost assumptions after Fife et al., Wounds 2012 2 Raffetto et al., J Clin Med 2020; Gohel et al., NEJM 2018 (EVRA); Warby & Maani, StatPearls 2023 3 Berrios-Torres et al., JAMA Surg 2017; Shepard et al., JAMA Surg 2013
The champion's dilemma
Your champion cares about what you're solving. They want you to succeed.
They've seen good ideas come and go before, and rarely because the technology wasn't right. There is only so much one person can do, and that limit is what stops most innovations ever reaching patients.
Most innovations are lost to the absence of a system around the person trying to prove them, not to the science.
The exchange
What we ask
One clinical champion. We will help define what success looks like, support them in achieving it, establish what value the product creates in their real-world environment, validate the claims the evidence supports, and turn that learning into something the institution can act on and the next champion can start from.
What we guarantee
You come away with independent proof that your value is real, and a repeatable way to prove it again with every subsequent champion. Every project ends with a decision-ready conclusion: whether the pre-specified outcome was achieved, which claims the evidence supports, what remains uncertain, and what the next adoption decision should be. If the work we control has not produced that level of clarity, we keep working until it does.
What the people involved say
It was almost like we were disconnected from the trial: giving space for outcomes to occur and following a rigorous methodology, as opposed to 'hey, try my product, what do you think?' Usually when it is done, it is done by a biostatistician paid for by a CRO, and that takes forever.
Franco Kraiselburd
Co-founder, Asclepii
People can't listen to Dr. Kimball about how the product will work for them without some concern about bias. The whole concept was a third-party analysis that was not biased, that could actually look at the data.
Dr. Traci Kimball MD MBA
Physician, The Wish Clinic; founder, EKagra Health
You've got to have papers behind it or it has issues later. We're working with another company where we're not doing an official study, and they're just running into all sorts of problems. It has nothing to do with the product.
Theresa Avsec
Leadership, Northeast Surgical Wound Care
We build everything that turns a willing champion into a successful one.
In four stages, we build everything your champion needs to succeed: the clinical evidence that satisfies a peer, the financial case that moves a committee, and a documented success story that every champion who follows can build on.
The Diagnostic
We map where your evidence stands against the published landscape for your category: what's supportable, where the gaps are, and what your champion needs to see.
The Impact Study
We design and run the study with your champion, not around them. A full picture of your technology's impact, in outcomes every stakeholder can stand behind.
The Evidence Package
The same findings, shaped for the three who decide. Your champion. Your administrator. Your committee. Each gets what they need to act.
The Champion Success Case
The first three stages become a blueprint your next champion picks up from day one. Your commercial conversations finally have something independent behind them. Each new site makes the next one easier.
Get your innovation to the patients it was built for.
Tell us about your technology and your champion. We'll tell you if we can help.
Book a Diagnostic